Dasatinib

Generic Name: Dasatinib

Brand Names: Sprycel

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₆ClN_₇O_₂S

CAS Number: 302962-49-8

Unique Ingredient Identifier: X78UG0A0RN

Background: Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...

Indication: Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Dasatinib In Waldenström Macroglobulinemia

Phase 1

Terminated

Conditions: Waldenstrom Macroglobulinemia
DASATINIB

Interventions: Drug: Dasatinib

First Posted Date: 2019-10-03

Last Posted Date: 2024-03-21

Lead Sponsor: Jorge J. Castillo, MD

Target Recruit Count: 3

Registration Number: NCT04115059

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Frontline Asciminib Combination in Chronic Phase CML

Phase 2

Active, not recruiting

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Asciminib
Drug: Dasatinib
Drug: Nilotinib 300 mg
Drug: Imatinib

First Posted Date: 2019-04-08

Last Posted Date: 2023-05-10

Lead Sponsor: University of Jena

Target Recruit Count: 125

Registration Number: NCT03906292

Locations: 🇩🇪
Universitätsklinikum Aachen Medizinische Klinik IV, Aachen, Germany
🇩🇪
Klinikum Bremen Mitte, Bremen, Germany
🇩🇪
Charite Universitätsmeditin Berlin, Campus Virchow Klinikum, Berlin, Germany

and more 18 locations

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

Completed

Conditions: CML - Philadelphia Chromosome
Chronic Myeloid Leukemia
Chronic Myeloid Leukemia, Chronic Phase
CML, Chronic Phase
CML (Chronic Myelogenous Leukemia

Interventions: Drug: Bosutinib
Drug: Dasatinib
Drug: Imatinib
Drug: Nilotinib

First Posted Date: 2019-03-22

Last Posted Date: 2023-01-11

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 45

Registration Number: NCT03885830

Locations: 🇺🇸
UNC Hospital, Chapel Hill, North Carolina, United States

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1

Terminated

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma

Interventions: Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat

First Posted Date: 2019-03-18

Last Posted Date: 2024-03-04

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03878524

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Phase 4

Conditions: Hematological Neoplasms

Interventions: Drug: Bortezomib
Drug: Eltrombopag
Drug: Imatinib
Drug: dasatinib
Drug: Pegaspargase
Drug: Anti-Infective Drugs
Drug: PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor

First Posted Date: 2019-02-18

Last Posted Date: 2020-01-10

Lead Sponsor: Wei Zhao

Target Recruit Count: 1500

Registration Number: NCT03844360

Locations: 🇨🇳
State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tanjin, Tianjin, China

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Phase 2

Active, not recruiting

Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions: Drug: Bosutinib
Drug: Dasatinib
Other: Laboratory Biomarker Analysis
Drug: Nilotinib
Drug: Ruxolitinib
Drug: Imatinib

First Posted Date: 2018-08-31

Last Posted Date: 2024-07-08

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 84

Registration Number: NCT03654768

Locations: 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States

and more 537 locations

Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Phase 2

Completed

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: Dasatinib

First Posted Date: 2018-08-10

Last Posted Date: 2023-09-22

Lead Sponsor: Hikma Pharmaceuticals LLC

Target Recruit Count: 56

Registration Number: NCT03625388

Locations: 🇯🇴
King Hussein Cancer Center (KHCC), Amman, Jordan
🇯🇴
Jordan University Hospital (JUH), Amman, Jordan
🇹🇳
Aziza Othmana Hospital, Tunis, Tunisia

and more 2 locations

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Phase 1

Recruiting

Conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
B-cell Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis

Interventions: Drug: ABL001
Drug: Dasatinib
Drug: Prednisone
Drug: Blinatumomab

First Posted Date: 2018-07-23

Last Posted Date: 2023-12-05

Lead Sponsor: Marlise Luskin, MD

Target Recruit Count: 40

Registration Number: NCT03595917

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment

Phase 2

Conditions: CML, Relapsed

Interventions: Drug: Dasatinib

First Posted Date: 2018-06-29

Last Posted Date: 2018-06-29

Lead Sponsor: Amsterdam UMC, location VUmc

Target Recruit Count: 134

Registration Number: NCT03573596

Locations: 🇫🇮
Helsinki University Hospital, Helsinki, Finland
🇳🇱
VU University medical center, Amsterdam, Netherlands
🇳🇱
Radboud University medical center, Nijmegen, Netherlands

and more 17 locations

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

Phase 2

Conditions: Leukemia, B-cell
Leukemia
Leukemia, Acute
Leukemia, Lymphoblastic

Interventions: Drug: Chidamide
Drug: Dasatinib

First Posted Date: 2018-06-20

Last Posted Date: 2022-07-01

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 120

Registration Number: NCT03564470

Locations: 🇨🇳
Department of Hematology, Nanfang Hospital, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy